CEPECO3: Efficacy of Two Protocols for Applying Fluorine Varnish to Deciduous Teeth

Sponsor
Universidade Ibirapuera (Other)
Overall Status
Suspended
CT.gov ID
NCT03827889
Collaborator
(none)
168
1
3
35.9
4.7

Study Details

Study Description

Brief Summary

Evidence that the data flow analysis tests, there are still no studies that show the clarity of the protocols of its application, including the interval and execution factors of applications, concentration of fluoridation and previous prophylaxis. That is, there are still large gaps regarding fluoride varnish applications. Thus, the objective of the present project is the selection of two protocols for application of fluid applications in active drugs in primary tooth enamel. The longitudinal follow-up will be performed in a period of 3, 6, 12, 18 and 24 months after the procedure. The progression of a subject will be evaluated clinically through the transition of ICDAS scores and assessment of the lesions (sound examination with superficial measurements) by visual examination, and the physician evaluates the efficacy and the ability to evaluate the therapeutic techniques and evaluation. treatment, cost and quality of life of participants

Condition or Disease Intervention/Treatment Phase
  • Procedure: WMP of fluoride varnish
  • Procedure: TWLP of fluoride varnish
  • Behavioral: DHP (educational intervention)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
168 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Efficacy of Two Protocols for Applying Fluorine Varnish to Initial Active Lesions of Deciduous Teeth: a Randomized Clinical Trial
Anticipated Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Jul 30, 2023
Anticipated Study Completion Date :
Dec 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: WMP of fluoride varnish

Whole mouth protocol group

Procedure: WMP of fluoride varnish
Application of fluoride varnish (drug of the intervention - Duraphat, Colgate) on all teeth, regardless of the lesions found

Experimental: TWLP of fluoride varnish

Tooth with lesion Protocol

Procedure: TWLP of fluoride varnish
application of the fluoride varnish (drug of the intervention - Duraphat, Colgate) only on the teeth with active initial caries lesions detected through visual examination after prophylaxis

Active Comparator: DHP (educational intervention)

Diet and Hygiene guidance Protocol

Behavioral: DHP (educational intervention)
The control group will receive diet and hygiene guidance (educational intervention) through verbal explanations and teeth brushing practices

Outcome Measures

Primary Outcome Measures

  1. PROGRESSION OF CARIES LESIONS (caries lesions inactivation assessment) [Every 6 months up to 24 months]

    Caries progression will be evaluated radiographically by three previously trained evaluators (through theoretical classes and evaluation of 13 clinical photographs) and calibrated. These examiners will not know the chronological order and compare the images two to two first by two evaluators and when there is disagreement between the two, the third examiner shall be called for tie-breaker. The possible progression of the treated caries lesion will be codified as: Present progression: Change in radiolucidity area of the Lesion Absent progression: No change in the area of radiolucidity of the lesion.

Secondary Outcome Measures

  1. Number of surfaces with NEW CARIES LESIONS [Up to 24 months]

    Detection of the presence of new lesions in deciduous and permanent teeth through visual inspection after dental cleaning. New lesions will be recorded using ICDAS scores.

  2. Children self-reported discomfort [baseline (Immediately after procedure)]

    The child's discomfort will be assessed immediately after the sequence of treatments performed in each session by the Wong-Baker face scale. Each face corresponds to a number in a numeric scale from 0 to 5, being 0 no discomfort and 5 maximum of discomfort. At the end, the averages of each score will be compared between the experimental groups.The patient will be asked to choose the face that is more similar to how he/she felt during the treatment. The answer should be given solely by the child, which means no parental or professional interferences.

  3. COST-EFFICACY of each protocol [up to 24 months]

    To evaluate the cost-efficacy of different protocols by total value in dollar of treatment in relation to efficacy.The quantities of all consumables used in each procedure will be annotated, as well as the time spent in each procedure, money and time will be combined to report the cost of procedures, measured by $/hour. In addition, we will verify the efficacy through the need for new surgical treatments or new caries lesions. In this way, we will compare the experimental groups according to the cost ($/hour) x the efficacy (need for new interventions). The costs of each treatment procedure will be calculated and compared with thresholds values for intervention by region, determined by World Health Organization (http://www.who.int/choice/costs/CER_levels/ en/).

Eligibility Criteria

Criteria

Ages Eligible for Study:
4 Years to 6 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Children with active carious lesions scores 1, 2 or 3 of the ICDAS in deciduous teeth
Exclusion Criteria:
  • Patients with special needs;

  • Patients using orthodontic appliances;

  • systemic diseases;

  • Teeth that present restorations, sealants, formation defects, deep caries lesions that may lead to pulp involvement, fistulae and / or abscesses;

  • teeth with spontaneous painful symptomatology.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Universidade Ibirapuera Sao Paulo Brazil 04661100

Sponsors and Collaborators

  • Universidade Ibirapuera

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Tamara Kerber Tedesco, PhD, Senior Lecturer, Universidade Ibirapuera
ClinicalTrials.gov Identifier:
NCT03827889
Other Study ID Numbers:
  • UNIB5
First Posted:
Feb 4, 2019
Last Update Posted:
Jun 1, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Tamara Kerber Tedesco, PhD, Senior Lecturer, Universidade Ibirapuera
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 1, 2022